MedTrace Logo

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

NCT07415018 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-14

No results posted yet for this study

Summary

To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.

Conditions

  • Leptomeningeal Disease

Interventions

PROCEDURE

MRI Scan

Given during standard of care

DRUG

VUEWAY

Given by IV

DRUG

Gadavist

Given by IV

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Rami Eldaya, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-22
Primary Completion
2027-07-31
Completion
2029-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07415018 on ClinicalTrials.gov